Page last updated: 2024-12-06

6-azathymine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-Azathymine is a synthetic pyrimidine analog that acts as an antimetabolite. It is structurally similar to thymine, a naturally occurring base in DNA, but with a nitrogen atom replacing the carbon at position 6. This structural similarity allows 6-azathymine to be incorporated into DNA during replication, leading to the disruption of DNA synthesis and function. 6-Azathymine has been investigated for its potential therapeutic applications, particularly in cancer treatment, due to its ability to inhibit cell growth and induce apoptosis. However, its clinical use has been limited due to its toxic side effects. Research on 6-azathymine continues, focusing on developing strategies to enhance its therapeutic efficacy and minimize its toxicity. 6-azathymine is also being explored for its potential as a research tool to study DNA replication and repair mechanisms.'

6-azathymine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-azathymine : A nucleobase analogue that is thymine in which the CH group at position 6 is replaced by nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70269
CHEMBL ID1741493
CHEBI ID102328
SCHEMBL ID814784
SCHEMBL ID10976253
MeSH IDM0119047

Synonyms (75)

Synonym
AKOS002350513
AKOS002339212
6-methyl-1,4-triazine-3,5-dione
6-azathymine
1,4-triazine-3,5(2h,4h)-dione, 6-methyl-
usaf cb-28
932-53-6
nsc3426
6-methyl-as-triazine-3,4h)-dione
wln: t6nmvmvj f1
5-methyl-6-azauracil
nsc-3426
as-triazine-3,4h)-dione, 6-methyl-
1,2,4-triazine-3,5(2h,4h)-dione, 6-methyl-
6-methyl-1,2,4-triazine-3,5(2h,4h)-dione
AO-089/25085002
nsc-38620
nsc38620
6-methyl-2h-1,2,4-triazine-3,5-dione
6-methyl-as-triazine-3,5-(2h,4h)-dione
BPBIO1_000381
azathymine, 6
PRESTWICK_662
NCGC00016550-01
cas-932-53-6
PRESTWICK2_000483
PRESTWICK3_000483
BSPBIO_000345
6-methyl-as-triazine-3,5-diol
einecs 213-253-9
as-triazine-3,5(2h,4h)-dione, 6-methyl-
3,5-dihydroxy-6-methyl-1,2,4-triazine
6-methyl-1,2,4-triazine-3,5-diol
nsc 38620
azathymine
ccris 3440
nsc 3426
6-methyl-1,2,4-triazine-3,5-dione
ai3-50849
PRESTWICK0_000483
PRESTWICK1_000483
SPBIO_002266
A-9600
A0556
xzwmzfqohtwgqe-uhfffaoysa-
inchi=1/c4h5n3o2/c1-2-3(8)5-4(9)7-6-2/h1h3,(h2,5,7,8,9)
STK895085
HMS1569B07
CHEBI:102328
AKOS002860206
A844488
HMS2096B07
NCGC00016550-02
zwx58t58za ,
unii-zwx58t58za
STL216013
F3098-5172
5-hydroxy-6-methyl-1,2,4-triazin-3(2h)-one
FT-0620951
SCHEMBL814784
6-methyl-2h-[1,2,4]triazine-3,5-dione
6-azathymine [mi]
CHEMBL1741493
SCHEMBL10976253
as-triazine-3,5-diol, 6-methyl-
6-methyl-as-triazine-3,5(2h,4h)-dione
Q27179036
mfcd00006457
DTXSID70239325
HY-136559
CS-0131257
SB73303
T71473
AS-56411
1,2,4-triazine-3,5(2h,4h)-dione,6-methyl-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitorAn EC 2.6.1.* (transaminase) inhibitor that interferes with the action of (R)-3-amino-2-methylpropionate--pyruvate transaminase (EC 2.6.1.40).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cyclic ketone
1,2,4-triazinesAny compound with a 1,2,4-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 2 and 4 of the core benzene ring structure.
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (68.42)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's4 (21.05)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.77 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]